SoaS score
6.9/10
Outlook-led
The story
The bet is the higher-margin CDMO and export mix, with three molecules commercialising and FDF revenue due Q4FY27; the latest call was markedly more guarded.
SoaS score
6.9/10
Outlook-led
Manufactures pharmaceutical intermediates and APIs, mainly NSAIDs like ketoprofen and loxoprofen, sold B2B in India and to 15 countries.
The story
The bet is the higher-margin CDMO and export mix, with three molecules commercialising and FDF revenue due Q4FY27; the latest call was markedly more guarded.
Growth Score
Exceptional
Revenue growth · 2Y view
Bear
>55%
Base
>61%
Bull
>64%
5 more live